The regenerative and protective actions of GHK-Cu make it a key player in maintaining overall cellular health
The method of claim 1 , wherein said at least one symptom is selected from the group consisting of: impaired or abnormal gait, neuronal oxidative stress, dementia, tremor, impaired balance, weakness, and personality changes
indica (Peskan-Berghofer et al., 2004)
Managing high B12 starts with identifying the causes of high vitamin B12, not just reducing intake
GHK-Cu published research history: - First isolated and characterized: 1973 - Continuous peer-reviewed publication: 50+ years - Published research covering: wound healing, skin biology, COPD, oxidative stress, bone, skeletal muscle, gastrointestinal, neurological, gene expression, aging - Mechanistic characterization: Multiple pathways identified, SIRT1 direct binding confirmed in 2025 - Cell and animal model validation: Extensive across multiple tissue types and species Matrixyl 3000 (palmitoyl tripeptide-1 + palmitoyl tetrapeptide-7) research: - Commercial introduction: Early 2000s - Research base: Primarily cosmetic science and dermatology literature - Mechanistic characterization: Primarily focused on TGF-beta receptor and IL-6 pathways - Depth: Narrower tissue focus, smaller body of published mechanistic research For researchers who need a compound with extensive published mechanistic context, detailed gene expression data, or research across multiple tissue types, GHK-Cu's research depth is substantially greater
